Supera Stent Study in Patients with Narrowing of the Leg Arteries
Zusammenfassung der Studie
This study investigates two different stents (vascular wall support) for the treatment of circulatory disorders caused by narrowing of the leg arteries. We compare whether the Supera® stent from the manufacturer Abbott is superior to the standard stent from the manufacturer Medtronic, the EverFlex™, in terms of primary patency rate and the need for re-intervention within 24 months. As part of the regular treatment, an angiography (vascular imaging with contrast agent) and balloon dilation (expansion of the narrowing) are performed. If this is sufficient to keep the leg arteries open and no stent is needed, the patient cannot participate in the study. Otherwise, the stent placement occurs, provided the patient continues to meet all study eligibility requirements. The stent placement procedure is carried out according to medical regulations, as well as outside the study. After stent placement, patients rest in bed for approximately 2-4 hours and can generally go home the same day or the following day, provided their health status is checked beforehand. Thereafter, patients must come to the treating hospital for examinations at months 1, 6, 12, and 24 to check their health status and response to therapy. For this purpose, physical and imaging examinations, such as ultrasound and pressure measurements (pulse status), are performed. The total study duration per patient is 24 months. This study is conducted as a prospective, randomized, multicenter parallel-group study. This means that a random process decides, comparable to flipping a coin, whether a patient receives the Supera® stent or an EverFlex™ stent; this is called randomization. The probability of receiving the Supera® stent is 50%. Both stents used in this study, Supera® or EverFlex™, are approved medical devices that are used in the same way as they are already used in everyday clinical practice.
(BASEC)
Untersuchte Intervention
Stents (vascular wall support) for the treatment of circulatory disorders caused by narrowing/occlusion of the leg arteries.
Stents used in this study: Supera® stent from the manufacturer Abbott or EverFlex™ Entrust™ or Protégé™ EverFlex™ from the manufacturer Medtronic
(BASEC)
Untersuchte Krankheit(en)
Circulatory disorders caused by narrowing/occlusion of the leg arteries
(BASEC)
- Patients with femoro-popliteal artery disease requiring a stent after balloon dilation - Available for 24 months - Men and women aged 18 years and older (BASEC)
Ausschlusskriterien
- Patients who cannot receive combined antiplatelet therapy (Aspirin 100 mg and Clopidogrel 75 mg) or anticoagulation therapy - Patients with known allergies to Nitinol (Nickel-Titanium) or contrast agents that cannot be medically treated - Previous stent implantation in the intended vascular segment (BASEC)
Studienstandort
St Gallen, Winterthur
(BASEC)
Sponsor
Kantonsspital Winterthur
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Prof. Dr. med. Christoph A. Binkert
+41 52 266 21 21
christoph.binkert@clutterksw.chKantonsspital Winterthur
(BASEC)
Allgemeine Auskünfte
Kantonsspital Winterthur KSW
(ICTRP)
Wissenschaftliche Auskünfte
Kantonsspital Winterthur KSW
(ICTRP)
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Zürich
(BASEC)
Datum der Bewilligung durch die Ethikkommission
18.04.2019
(BASEC)
ICTRP Studien-ID
NCT03941314 (ICTRP)
Offizieller Titel (Genehmigt von der Ethikkommission)
A prospective randomized, parallel-group, multicentre, superiority trial of the SUPERA peripheral stent system in patients with femoro-popliteal artery disease (BASEC)
Wissenschaftlicher Titel
A Prospective Randomized, Parallel-group, Multicentre, Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease (ICTRP)
Öffentlicher Titel
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease (ICTRP)
Untersuchte Krankheit(en)
Peripheral Arterial Disease (ICTRP)
Untersuchte Intervention
Device: Supera? Peripheral Stent System;Device: EverFlex? Self-Expanding Peripheral Stent System (ICTRP)
Studientyp
Interventional (ICTRP)
Studiendesign
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)
Ein-/Ausschlusskriterien
Gender: All
Maximum age: N/A
Minimum age: 18 Years
Inclusion Criteria:
- Patients with femoro-popliteal artery disease, who will require a stent
femoro-popliteal following failed percutaneous transluminal angioplasty (PTA)
- Target Lesion length <200mm
- Planned follow-up available for at least 24 months
- Written informed consent to participate in the study and agreement to comply with the
study protocol must be obtained from the patient prior to initiation of any
study-mandated procedure and randomization
Exclusion Criteria:
- Life expectancy <24 months
- Patients who cannot receive dual antiplatelet therapy (aspirin 100mg and clopidogrel
75mg) or anticoagulation therapy
- Patients with known allergies to: nitinol (nickel titanium); or contrast agent, that
cannot be medically managed
- Participation in another study with investigational drug/device within the 30 days
preceding and during the present study
- Previous enrolment into the current study
- Prior stenting at the location of intended stenting
- Patients who are judged to have a lesion that prevents complete inflation of an
angioplasty balloon or proper placement of the stent or stent delivery system
- Enrolment of study investigator, his/her family members, employees and other dependent
persons
- If female and of childbearing potential: known pregnancy or a positive urine pregnancy
test (confirmed by a positive serum pregnancy test), or lactating
(ICTRP)
nicht verfügbar
Primäre und sekundäre Endpunkte
Difference in primary patency rate (proportion of patients classed as treatment succsess) (ICTRP)
Difference in primary patency rate;Difference in target lesion/vessel revascularization;Difference in amputation;Difference in time to restenosis (and time to target lesion revascularization due to restenosis);Difference in Anklre Brachial Index;Difference in Fontaine classification (ICTRP)
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
Abbott;Cantonal Hospital of St. Gallen (ICTRP)
Weitere Kontakte
Christoph A Binkert, MD, Kantonsspital Winterthur KSW (ICTRP)
Sekundäre IDs
CTU 17/037, BASEC 2019-00312 (ICTRP)
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
https://clinicaltrials.gov/ct2/show/NCT03941314 (ICTRP)
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar